Free Practice Questions for SCDM CCDM Exam

Answer : A

In an EDC system, Site Study Coordinators are typically responsible for data entry and updates, as they are the site-level personnel who record subject data from source documents into the electronic CRFs (eCRFs).

The Good Clinical Data Management Practices (GCDMP, Chapter: EDC Systems) outlines that data entry and modification privileges should only be granted to qualified site personnel who have completed EDC system training and are listed on the study delegation log. These users directly handle patient-level data entry and correction.

In contrast:

Clinical Study Monitors (B) review and verify data but do not enter or modify it.

EDC System Administrators (C) manage user access and configuration settings, not study data.

Study Statisticians (D) work with extracted, cleaned datasets but never have data modification privileges.

Thus, option A (Site Study Coordinator) correctly identifies the role with authorized data entry and update privileges.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.2 -- User Roles and Access Permissions

ICH E6(R2) GCP, Section 4.1 -- Investigator Responsibilities for Data Accuracy

FDA 21 CFR Part 11 -- User Access and Accountability in Electronic Systems

Answer : D

When a company transitions from paper-based data capture to Electronic Data Capture (EDC) systems, one of the most critical areas requiring procedural updates is the Data Review and Validation SOP. The introduction of EDC systems fundamentally changes how data is collected, reviewed, validated, and queried.

According to the Good Clinical Data Management Practices (GCDMP), the implementation of EDC introduces real-time data entry and review, automated edit checks, and electronic query management. These functionalities necessitate revised procedures to define how data validation, discrepancy management, and monitoring are conducted electronically. The SOP must specify roles, responsibilities, system access controls, and processes for electronic source verification (eSource), ensuring compliance with 21 CFR Part 11 and ICH E6 (R2) requirements.

Other SOPs such as Handling External Data or Data Backup may require minor updates, but the Data Review and Validation SOP undergoes the most extensive change because EDC technology shifts validation responsibilities from post-data entry review to real-time oversight within the system.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 6.3 -- SOP Adaptation for EDC Implementation

FDA 21 CFR Part 11 -- Electronic Records; Electronic Signatures

ICH E6 (R2) Good Clinical Practice, Section 5.5.3 -- Data Handling and Validation

Answer : D

In this scenario, the variable of interest---range of motion (ROM)---is a clinically measured, observer-dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).

According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments.

Other options, while valuable, address only data consistency or plausibility after collection:

Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error.

Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency.

The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.

Reference (CCDM-Verified Sources):

Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 -- Measurement Quality and Verification

ICH E6 (R2) Good Clinical Practice, Section 2.13 -- Quality Systems and Data Integrity

FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 -- Quality Control of Clinician-Assessed Data

SCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures

Answer : C

In managing site data timeliness, the most actionable and effective tool is a report listing all outstanding (missing or incomplete) CRFs.

According to GCDMP (Chapter: Communication and Study Reporting), Data Managers must provide site-level performance reports highlighting:

Outstanding CRFs not yet entered,

Unresolved queries, and

Pending data corrections.

Such reports help sites prioritize and address data gaps efficiently.

Option A and D are historical metrics without actionable context.

Option B gives a general overview but lacks specific site-level actionability.

Hence, option C (List of outstanding forms) provides the clearest and most motivating feedback to sites for timely data entry and query resolution.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Communication and Study Reporting, Section 5.3 -- Data Timeliness and Reporting Metrics

ICH E6(R2) GCP, Section 5.1.1 -- Sponsor Oversight and Data Communication Requirements

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 -- Site-Level Data Timeliness Reporting

Answer : D

Once the Case Report Form (CRF) has been finalized and database development has begun, the next primary responsibility of the Data Manager is to prepare a Data Validation Plan (DVP) for the clinical database.

According to the GCDMP (Chapter: Database Design and Build), the DVP documents all planned validation procedures --- including edit checks, cross-form validations, discrepancy management workflows, and system testing requirements. This ensures that data entry, processing, and cleaning are consistent with protocol requirements and that the database will produce reliable, auditable data for analysis.

While system requirement specifications (option B) are prepared before database development begins, and timeline planning (option C) occurs during the study startup phase, the DVP is the critical next step post-CRF approval to define and validate system logic before user acceptance testing (UAT).

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Build, Section 6.4 -- Data Validation Plan (DVP) Development

ICH E6 (R2) GCP, Section 5.5.3 -- Validation of Computerized Systems

FDA 21 CFR Part 11 -- System Validation Requirements for Electronic Records